# REZILIENT3 (NCT05973773)

> REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

No report yet. It can be ordered.

- Drugs tested: zipalertinib
- Indication: untreated EGFR exon 20 insertion-mutated advanced nonsquamous NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05973773
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Taiho Oncology, Inc.
- Conditions: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
- Interventions: TAS6417
- Enrollment: 285
- Primary outcome: Part A and B: The rate and severity of treatment emergent AEs
- Primary outcome: Part A and Part B: Progression-free survival (PFS) by blinded independent central review (BICR)
- Primary outcome: Part A: The rate and severity of DLTs according to the NCI-Common Terminology Criteria of Adverse Events (CTCAE) v5.0 during Cycle 1

## Indexed commentary on REZILIENT3 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 85
- Podcasts: 14
- YouTube: 11
- Bluesky threads: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=rezilient3-nct05973773

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05973773", "email": "<work email>"}; the inbox owner confirms by the emailed link.